Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integrative analysis of hub genes for recurrent pregnancy loss with antiphospholipid syndrome: integrated bioinformatics analysis, machine learning and experimental validation.

Frontiers in immunology·2026

Same author

Seasonal Metabolic Profiling and Anti-Inflammatory Potential of <i>Spatholobus suberectus</i> Leaves Based on Metabolomics and Network Pharmacology.

Plants (Basel, Switzerland)·2026

Same author

Structural basis for TCR recognition of a Rac1 neoantigen arising from anchor residue mutation.

Journal of structural biology·2026

Same author

Neoantigen-based TCR-T therapy in solid tumors.

International review of cell and molecular biology·2026

Same author

Yeast surface display meets immunotherapy: unlocking the potential of T cells.

Cytotherapy·2026

Same author

Assessment of carbohydrates binding with their receptors on the cell membrane and carbohydrates targeted nano-drugs entry cell.

Colloids and surfaces. B, Biointerfaces·2026

Search research articles

Related Experiment Video

Updated: Jul 11, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy.

Dandan Yang¹, Zhihui Duan¹, Ping Yuan¹

¹Laboratory of Structural Immunology, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.

Biochemical and Biophysical Research Communications

|November 9, 2023

Summary

T-cell receptor (TCR)-engineered T cell therapy shows promise for solid tumors. Neoantigen-specific TCR-T cell therapy, alongside optimizing the tumor microenvironment and TCRs, offers a promising future direction for cancer treatment.

Keywords:

Adoptive cell therapy Neoantigen T cell receptor TCR-T Tumor antigen

More Related Videos

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jul 11, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Oncology
Immunotherapy
Cell Therapy

Background:

T-cell receptor (TCR)-engineered T cell therapy has advanced significantly in treating solid tumors, with some approaches entering clinical trials.
Understanding the current landscape of TCR-T cell therapy is crucial for guiding future research and clinical applications.

Purpose of the Study:

To review the progress of TCR-T cell therapy in solid tumor treatment.
To classify tumor antigens and analyze TCR-T cell therapy targeting these antigens.
To explore strategies for enhancing TCR-T cell therapy efficacy.

Main Methods:

Classification of tumor antigens into four categories: tumor-associated, tumor-specific, oncogenic virus-expressed, and abnormal protein modification-related.
Detailed review of TCR-T cell therapy effects in clinical and preclinical trials targeting these antigens.
Summary of optimization strategies for improving TCR-T cell therapy.

Main Results:

Neoantigen-specific TCR-T cell therapy is identified as a highly promising approach for solid tumors.
Various TCR-T cell therapies targeting different antigen types have shown efficacy in trials.
Optimization strategies including modulating the tumor microenvironment and enhancing TCR pairing and affinity are crucial for therapeutic success.

Conclusions:

TCR-T cell therapy represents a significant advancement in solid tumor treatment.
Targeting neoantigens with TCR-engineered T cells holds substantial potential for future cancer therapies.
Further research into antigen selection and therapeutic optimization is essential for maximizing the impact of TCR-T cell therapy.